180 related articles for article (PubMed ID: 37968696)
1. Integrative whole-genome and transcriptome analysis of HER2-amplified metastatic breast cancer.
Verschoor N; Smid M; Jager A; Sleijfer S; Wilting SM; Martens JWM
Breast Cancer Res; 2023 Nov; 25(1):145. PubMed ID: 37968696
[TBL] [Abstract][Full Text] [Related]
2. Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases.
Priedigkeit N; Hartmaier RJ; Chen Y; Vareslija D; Basudan A; Watters RJ; Thomas R; Leone JP; Lucas PC; Bhargava R; Hamilton RL; Chmielecki J; Puhalla SL; Davidson NE; Oesterreich S; Brufsky AM; Young L; Lee AV
JAMA Oncol; 2017 May; 3(5):666-671. PubMed ID: 27926948
[TBL] [Abstract][Full Text] [Related]
3. Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance.
Saunus JM; Quinn MC; Patch AM; Pearson JV; Bailey PJ; Nones K; McCart Reed AE; Miller D; Wilson PJ; Al-Ejeh F; Mariasegaram M; Lau Q; Withers T; Jeffree RL; Reid LE; Da Silva L; Matsika A; Niland CM; Cummings MC; Bruxner TJ; Christ AN; Harliwong I; Idrisoglu S; Manning S; Nourse C; Nourbakhsh E; Wani S; Anderson MJ; Fink JL; Holmes O; Kazakoff S; Leonard C; Newell F; Taylor D; Waddell N; Wood S; Xu Q; Kassahn KS; Narayanan V; Taib NA; Teo SH; Chow YP; kConFab ; Jat PS; Brandner S; Flanagan AM; Khanna KK; Chenevix-Trench G; Grimmond SM; Simpson PT; Waddell N; Lakhani SR
J Pathol; 2015 Nov; 237(3):363-78. PubMed ID: 26172396
[TBL] [Abstract][Full Text] [Related]
4. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
[TBL] [Abstract][Full Text] [Related]
5. Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA
Cheng F; Zhao J; Hanker AB; Brewer MR; Arteaga CL; Zhao Z
Breast Cancer Res Treat; 2016 Dec; 160(3):457-474. PubMed ID: 27771839
[TBL] [Abstract][Full Text] [Related]
6. Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer.
Park YH; Shin HT; Jung HH; Choi YL; Ahn T; Park K; Lee A; Do IG; Kim JY; Ahn JS; Park WY; Im YH
Oncotarget; 2015 Oct; 6(31):32027-38. PubMed ID: 26397225
[TBL] [Abstract][Full Text] [Related]
7. Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas.
Berrino E; Annaratone L; Bellomo SE; Ferrero G; Gagliardi A; Bragoni A; Grassini D; Guarrera S; Parlato C; Casorzo L; Panero M; Sarotto I; Giordano S; Cereda M; Montemurro F; Ponzone R; Crosetto N; Naccarati A; Sapino A; Marchiò C
Genome Med; 2022 Aug; 14(1):98. PubMed ID: 36038884
[TBL] [Abstract][Full Text] [Related]
8. HER2-low expression in patients with advanced or metastatic solid tumors.
Uzunparmak B; Haymaker C; Raso G; Masciari S; Wang L; Lin H; Gorur A; Kirby B; Cimo AM; Kennon A; Ding Q; Urschel G; Yuan Y; Feng G; Rizvi Y; Hussain A; Zhu C; Kim P; Abbadessa G; Subbiah V; Yap TA; Rodon J; Piha-Paul SA; Meric-Bernstam F; Dumbrava EE
Ann Oncol; 2023 Nov; 34(11):1035-1046. PubMed ID: 37619847
[TBL] [Abstract][Full Text] [Related]
9. Combined analysis of receptor expression reflects inter-and intra-tumor heterogeneity in HR+/HER2+ breast cancer.
Ju J; Du F; Gao SL; Si YR; Hu NL; Liu DX; Wang X; Yue J; Zheng FC; Kang YK; Yang ZX; Ma F; Xu BH; Yuan P
Breast Cancer Res Treat; 2022 Jul; 194(2):221-230. PubMed ID: 35699854
[TBL] [Abstract][Full Text] [Related]
10. Analysis of clinical features, genomic landscapes and survival outcomes in HER2-low breast cancer.
Jin J; Li B; Cao J; Li T; Zhang J; Cao J; Zhao M; Wang L; Wang B; Tao Z; Hu X
J Transl Med; 2023 Jun; 21(1):360. PubMed ID: 37264417
[TBL] [Abstract][Full Text] [Related]
11. Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer.
Tanioka M; Fan C; Parker JS; Hoadley KA; Hu Z; Li Y; Hyslop TM; Pitcher BN; Soloway MG; Spears PA; Henry LN; Tolaney S; Dang CT; Krop IE; Harris LN; Berry DA; Mardis ER; Winer EP; Hudis CA; Carey LA; Perou CM
Clin Cancer Res; 2018 Nov; 24(21):5292-5304. PubMed ID: 30037817
[No Abstract] [Full Text] [Related]
12. Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients.
Aktas B; Kasimir-Bauer S; Müller V; Janni W; Fehm T; Wallwiener D; Pantel K; Tewes M;
BMC Cancer; 2016 Jul; 16():522. PubMed ID: 27456970
[TBL] [Abstract][Full Text] [Related]
13. Molecular characterization of
Owen DR; Wong HL; Bonakdar M; Jones M; Hughes CS; Morin GB; Jones SJM; Renouf DJ; Lim H; Laskin J; Marra M; Yip S; Schaeffer DF
Cold Spring Harb Mol Case Stud; 2018 Apr; 4(2):. PubMed ID: 29438965
[No Abstract] [Full Text] [Related]
14. Updates on breast biomarkers.
Najjar S; Allison KH
Virchows Arch; 2022 Jan; 480(1):163-176. PubMed ID: 35029776
[TBL] [Abstract][Full Text] [Related]
15. Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer.
Cejalvo JM; Martínez de Dueñas E; Galván P; García-Recio S; Burgués Gasión O; Paré L; Antolín S; Martinello R; Blancas I; Adamo B; Guerrero-Zotano Á; Muñoz M; Nucíforo P; Vidal M; Pérez RM; Chacón López-Muniz JI; Caballero R; Peg V; Carrasco E; Rojo F; Perou CM; Cortés J; Adamo V; Albanell J; Gomis RR; Lluch A; Prat A
Cancer Res; 2017 May; 77(9):2213-2221. PubMed ID: 28249905
[TBL] [Abstract][Full Text] [Related]
16. Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study.
Ross JS; Gay LM; Nozad S; Wang K; Ali SM; Boguniewicz A; Khaira D; Johnson A; Elvin JA; Vergilio JA; Suh J; Miller VA; Stephens PJ
Breast Cancer Res Treat; 2016 Jan; 155(2):405-13. PubMed ID: 26762307
[TBL] [Abstract][Full Text] [Related]
17. Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer.
Hensing WL; Gerratana L; Clifton K; Medford AJ; Velimirovic M; Shah AN; D'Amico P; Reduzzi C; Zhang Q; Dai CS; Denault EN; Bagegni NA; Opyrchal M; Ademuyiwa FO; Bose R; Behdad A; Ma CX; Bardia A; Cristofanilli M; Davis AA
Clin Cancer Res; 2023 Aug; 29(16):3092-3100. PubMed ID: 37265453
[TBL] [Abstract][Full Text] [Related]
18. Integrated multi-omics profiling of high-grade estrogen receptor-positive, HER2-negative breast cancer.
Wang K; Li L; Franch-Expósito S; Le X; Tang J; Li Q; Wu Q; Bassaganyas L; Camps J; Zhang X; Li H; Foukakis T; Xiang T; Wu J; Ren G
Mol Oncol; 2022 Jun; 16(12):2413-2431. PubMed ID: 34146382
[TBL] [Abstract][Full Text] [Related]
19. An integrated model of the transcriptome of HER2-positive breast cancer.
Kalari KR; Necela BM; Tang X; Thompson KJ; Lau M; Eckel-Passow JE; Kachergus JM; Anderson SK; Sun Z; Baheti S; Carr JM; Baker TR; Barman P; Radisky DC; Joseph RW; McLaughlin SA; Chai HS; Camille S; Rossell D; Asmann YW; Thompson EA; Perez EA
PLoS One; 2013; 8(11):e79298. PubMed ID: 24223926
[TBL] [Abstract][Full Text] [Related]
20. NRF1 motif sequence-enriched genes involved in ER/PR -ve HER2 +ve breast cancer signaling pathways.
Ramos J; Das J; Felty Q; Yoo C; Poppiti R; Murrell D; Foster PJ; Roy D
Breast Cancer Res Treat; 2018 Nov; 172(2):469-485. PubMed ID: 30128822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
